Recent News

• 10.06.2025 - MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
• 10.06.2025 - MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
• 09.22.2025 - MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
• 09.22.2025 - MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
• 08.06.2025 - MaxCyte Second Quarter Earnings Conference Call
• 08.06.2025 - MaxCyte Second Quarter Earnings Conference Call
• 08.06.2025 - MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
• 08.06.2025 - MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

Recent Filings

• 09.22.2025 - EX-99.1 EX-99.1
• 09.22.2025 - 8-K Current report
• 08.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.26.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.11.2025 - 8-K Current report